What Mazdutide is
Mazdutide is a dual glucagon/GLP-1 receptor agonist developed by Innovent Biologics in China under license from Eli Lilly. It adds glucagon-receptor activity to the familiar GLP-1 mechanism, which is thought to increase energy expenditure on top of appetite suppression. In China it is marketed as Xinermei; in the United States it remains investigational.
Mechanically, Mazdutide is a dual glucagon (GCG) and GLP-1 receptor agonist — an oxyntomodulin analogue, the first dual GCG/GLP-1 agonist to reach any market.
What the trials show
In the Chinese Phase 3 GLORY program, mazdutide 9 mg produced about 16.7% average weight loss overall at 60 weeks — up to roughly 20% in the subgroup without diabetes (GLORY-2) — and the 6 mg dose about 14.8% at 48 weeks (GLORY-1), versus roughly 0.5% on placebo. These are strong results, but they come from trials conducted in Chinese populations; there is no completed head-to-head against tirzepatide or semaglutide in a US population, and the top-line figures reflect full-adherence analyses.
Can you get Mazdutide yet?
You cannot get mazdutide in the United States. It is approved and marketed in China but has not been filed for or approved by the FDA, and US development is only at Phase 2. Independent trackers guess a US approval, if it comes, would be years away — those are estimates, not company guidance. Anything sold online as "mazdutide" to US buyers is not the approved Chinese product and is unverified.
The single most important point: approval in China does not mean availability in the US. Mazdutide is a foreign-approved, US-investigational drug — never treat its Chinese marketing as US availability.
The options you can actually get now
While Mazdutide moves through trials, the FDA-approved GLP-1 medicines are available today. If weight loss is the goal, see our comparison of the best approved GLP-1 options, the semaglutide and tirzepatide hubs, and the full list of GLP-1 medications.